TeamDrive
RUS

FPI conducts preclinical trials of drug intended to save seriously injured

14 August 2018

GMP News

Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

Liquid mixtures based on xenon were developed within the framework of the FPI project, which is being carried out in collaboration with the Institute of Cell Biophysics RAS from 2015. The ultimate goal of the project is to create a medicine to extend the “golden hour” by induction of an artificial hypobiosis state in human, similar to the state of hibernation in bears.

“I think that human trials can begin no earlier than three years from now. We have already assessed the effectiveness of the drug, but its safety is not yet assessed,” Mr. Kovtun said.

According to him, it is necessary to go through the entire phase of preclinical studies with testing the drug in no less than four species of animals. Previously, scientists gradually studied the effect of the drug on different groups of animals, starting from small ones: mice, rats, rabbits.

“Now we proceed to the next intermediate experiment on dwarf pigs, which have some physiological parameters that are very similar to humans, especially those of the circulatory system. This is a very reliable object for such intermediate studies. Then we will conduct studies in primates,” commented Mr. Kovtun.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more